HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prediction of lung cancer based on serum biomarkers by gene expression programming methods.

Abstract
In diagnosis of lung cancer, rapid distinction between small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) tumors is very important. Serum markers, including lactate dehydrogenase (LDH), C-reactive protein (CRP), carcino-embryonic antigen (CEA), neurone specific enolase (NSE) and Cyfra21-1, are reported to reflect lung cancer characteristics. In this study classification of lung tumors was made based on biomarkers (measured in 120 NSCLC and 60 SCLC patients) by setting up optimal biomarker joint models with a powerful computerized tool - gene expression programming (GEP). GEP is a learning algorithm that combines the advantages of genetic programming (GP) and genetic algorithms (GA). It specifically focuses on relationships between variables in sets of data and then builds models to explain these relationships, and has been successfully used in formula finding and function mining. As a basis for defining a GEP environment for SCLC and NSCLC prediction, three explicit predictive models were constructed. CEA and NSE are frequently- used lung cancer markers in clinical trials, CRP, LDH and Cyfra21-1 have significant meaning in lung cancer, basis on CEA and NSE we set up three GEP models-GEP 1(CEA, NSE, Cyfra21-1), GEP2 (CEA, NSE, LDH), GEP3 (CEA, NSE, CRP). The best classification result of GEP gained when CEA, NSE and Cyfra21-1 were combined: 128 of 135 subjects in the training set and 40 of 45 subjects in the test set were classified correctly, the accuracy rate is 94.8% in training set; on collection of samples for testing, the accuracy rate is 88.9%. With GEP2, the accuracy was significantly decreased by 1.5% and 6.6% in training set and test set, in GEP3 was 0.82% and 4.45% respectively. Serum Cyfra21-1 is a useful and sensitive serum biomarker in discriminating between NSCLC and SCLC. GEP modeling is a promising and excellent tool in diagnosis of lung cancer.
AuthorsZhuang Yu, Xiao-Zheng Chen, Lian-Hua Cui, Hong-Zong Si, Hai-Jiao Lu, Shi-Hai Liu
JournalAsian Pacific journal of cancer prevention : APJCP (Asian Pac J Cancer Prev) Vol. 15 Issue 21 Pg. 9367-73 ( 2014) ISSN: 2476-762X [Electronic] Thailand
PMID25422226 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Biomarkers, Tumor
  • CA-125 Antigen
  • Carcinoembryonic Antigen
  • C-Reactive Protein
  • Phosphopyruvate Hydratase
Topics
  • Aged
  • Biomarkers, Tumor (blood, genetics)
  • C-Reactive Protein (analysis)
  • CA-125 Antigen (blood)
  • Carcinoembryonic Antigen (blood)
  • Carcinoma, Non-Small-Cell Lung (blood, diagnosis, genetics)
  • Cohort Studies
  • Diagnosis, Differential
  • Female
  • Gene Expression Profiling (methods)
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Lung Neoplasms (blood, diagnosis)
  • Male
  • Middle Aged
  • Neoplasm Invasiveness (pathology)
  • Neoplasm Staging
  • Phosphopyruvate Hydratase (blood)
  • Predictive Value of Tests
  • Retrospective Studies
  • Sensitivity and Specificity
  • Small Cell Lung Carcinoma (blood, diagnosis, genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: